Neuromielitis óptica. Actualización de los conceptos clínicos y fisiopatológicos de la enfermedad
DOI:
https://doi.org/10.51987/Rev.Hosp.Ital.B.Aires.v31i1.997Resumen
.
Descargas
Referencias
Wingerchuk dM, lennon va, lucchinetti cF, et al. the spectrum of neuromyelitis optica. lancet neurol. 2007;6(9):805-15. DOI: https://doi.org/10.1016/S1474-4422(07)70216-8
Wingerchuk dM, Hogancamp WF, o’Brien Pc , et al. the clinical course of neuromyelitis optica (devic’s syndrome). neurology. 1999;53(5):1107-14. DOI: https://doi.org/10.1212/WNL.53.5.1107
Weinshenker BG. neuromyelitis optica: what it is and what it might be. lancet. 2003;361(9361):889-90. errata en: lancet. 2003;362(9383):582 DOI: https://doi.org/10.1016/S0140-6736(03)12784-5
albutt tc. on the ophthalmoscopic signs of spinal disease. lancet. 1870;1(2420):76-8. DOI: https://doi.org/10.1016/S0140-6736(02)68218-2
devic e. Myelite subague complique de nevrite optique. Bull Med. 1894;8:1033-4.
Jacob a, Matiello M, Wingerchuk dM, et al. neuromyelitis optica: changing concepts. J neuroimmunol. 2007;187(1-2):126-38. DOI: https://doi.org/10.1016/j.jneuroim.2007.04.009
Polman cH, reingold sc, edan G, et al. diagnostic criteria for multiple sclerosis: 2005 revisions to the “Mcdonald criteria”. ann neurol. 2005;58(6):840-6 DOI: https://doi.org/10.1002/ana.20703
cabre P, Heinzlef o, Merle H, et al. Ms and neuromyelitis optica in Martinique (French West indies). neurology. 2001;56(4):507-14. DOI: https://doi.org/10.1212/WNL.56.4.507
de seze J, lebrun c, stojkovic t, et al. is devic’s neuromyelitis optica a separate disease? a comparative study with multiple sclerosis. Mult scler. 2003;9(5):521-5. DOI: https://doi.org/10.1191/1352458503ms947oa
Ghezzi a, Bergamaschi r, Martinelli v, et al. clinical characteristics, course and prognosis of relapsing devic’s neuromyelitis optica. J neurol. 2004;251(1):47-52 DOI: https://doi.org/10.1007/s00415-004-0271-0
Wingerchuk dM, lennon va, Pittock sJ, et al. revised diagnostic criteria for neuromyelitis optica. neurology. 2006;66(10):1485-9. DOI: https://doi.org/10.1212/01.wnl.0000216139.44259.74
lennon va, Wingerchuk dM, Kryzer tJ, et al. a serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. lancet. 2004;364(9451):2106-12. DOI: https://doi.org/10.1016/S0140-6736(04)17551-X
lennon va, Kryzer tJ, Pittock sJ, et al. igG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J exp Med. 2005;202(4):473-7. DOI: https://doi.org/10.1084/jem.20050304
domingues rB, Kuster GW, lanes F, et al. recurrent neuromyelitis optica with diffuse central nervous system involvement: case report. arq neuropsiquiatr. 2004;62(2B):543-6. DOI: https://doi.org/10.1590/S0004-282X2004000300032
Jouhadi Z, ouazzani i, abid a, et al. neuromyelite optique de devic et hepatite virale a. a propos d’une observation pediatrique. rev neurol (Paris). 2004;160(12):1198-202 DOI: https://doi.org/10.1016/S0035-3787(04)71167-4
Papais-alvarenga rM, Miranda-santos cM, Puccioni-sohler M, et al. optic neuromyelitis syndrome in Brazilian patients. J neurol neurosurg Psychiatry. 2002;73(4):429-35. DOI: https://doi.org/10.1136/jnnp.73.4.429
Fukazawa t, Yamasaki K, ito H, et al. Both the Hla-c PB1 and -drB1 alleles correlate with risk for multiple sclerosis in Japanese: clinical phenotypes and gender as important factors. tissue antigens. 2000;55(3):199-205. DOI: https://doi.org/10.1034/j.1399-0039.2000.550302.x
Wingerchuk dM, Weinshenker BG. neuromyelitis optica: clinical predictors of a relapsing course and survival. neurology. 2003;60(5):848-53. DOI: https://doi.org/10.1212/01.WNL.0000049912.02954.2C
Pittock sJ, lennon va, Krecke K, et al. Brain abnormalities in neuromyelitis optica. arch neurol. 2006;63(3):390-6. DOI: https://doi.org/10.1001/archneur.63.3.390
roemer sF, Parisi Je, lennon va, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain. 2007;130(Pt 5):1194-205 DOI: https://doi.org/10.1093/brain/awl371
nakashima i, Fujihara K, Miyazawa i, et al. clinical and Mri features of Japanese patients with multiple sclerosis positive for nMo-igG. J neurol neurosurg Psychiatry. 2006;77(9):1073-5. DOI: https://doi.org/10.1136/jnnp.2005.080390
Pittock sJ, Weinshenker BG, lucchinetti cF, et al. neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. arch neurol. 2006;63(7):964-8. DOI: https://doi.org/10.1001/archneur.63.7.964
Jarius s, Paul F, Franciotta d, et al. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. nat clin Pract neurol. 2008;4(4):202-14. DOI: https://doi.org/10.1038/ncpneuro0764
nielsen s, nagelhus ea, amiry-Moghaddam M, et al. specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J neurosci. 1997;17(1):171-80 DOI: https://doi.org/10.1523/JNEUROSCI.17-01-00171.1997
Manley Gt, Fujimura M, Ma t, et al. aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. nat Med. 2000;6(2):159-63. DOI: https://doi.org/10.1038/72256
lehmann Hc, Hartung HP, Hetzel Gr, et al. Plasma exchange in neuroimmunological disorders: Part 1: rationale and treatment of inflammatory central nervous system disorders. arch neurol. 2006;63(7):930-5 DOI: https://doi.org/10.1001/archneur.63.7.930
Weinshenker BG, o’Brien Pc, Petterson tM, et al. a randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. ann neurol. 1999;46(6):878-86. DOI: https://doi.org/10.1002/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q
Falcini F, trapani s, ricci l, et al. sustained improvement of a girl affected with devic’s disease over 2 years of mycophenolate mofetil treatment. rheumatology (oxford). 2006;45(7):913-5. DOI: https://doi.org/10.1093/rheumatology/kei263
Weinstock-Guttman B, ramanathan M, lincoff n, et al. study of mitoxantrone for the treatment of recurrent neuromyelitis optica (d evic disease). arch neurol. 2006;63(7):957-63. DOI: https://doi.org/10.1001/archneur.63.7.957
cree B a, lamb s, Morgan K, et al. an open label study of the effects of rituximab in neuromyelitis optica. neurology. 2005;64(7):1270-2 DOI: https://doi.org/10.1212/01.WNL.0000159399.81861.D5
Descargas
Compartir artículo
Publicado
Número
Sección
Licencia
Derechos de autor 2011 Juan Ignacio Rojas, Sergio Javier González, Liliana Patrucco, Edgardo Cristiano
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
